Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record.

Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.

Segal, Neil Howard, Antonia, Scott Joseph, Brahmer, Julie R., Maio, Michele, Blake-Haskins, Andy, Li, Xia, Vasselli, Jim, Ibrahim, Ramy A., Lutzky, Jose, Khleif, Samir·2014·Journal of Clinical Oncology

Abstract

3002^ Background: Checkpoint blockade of the PD-1/PD-L1 and CTLA-4 pathways has shown to be active in multiple tumor types. MEDI4736 is a human IgG1 monoclonal antibody which binds specifically to PD-L1, preventing binding to PD-1 and CD80. In phase I, MEDI4736 showed acceptable safety (no maximal tolerated dose identified). With evidence of clinical activity in phase I, an expansion study was initiated in multiple cancer types including NSCLC, melanoma (cutaneous and ocular), gastroesophageal, hepatocellular carcinoma, pancreatic, SCCHN and triple negative breast cancer. Methods: 10 - 20 pts were initially enrolled per tumor type, with expansion allowed upon observation of clinical activity. MEDI4736 was administered as 10 mg/kg IV every 2 weeks for 12 months. Retreatment was permitted for progression after 12 months of therapy. Response was assessed by RECIST v1.1. Results: The expansion cohorts were initiated in Sep 2013. As of Jan 17, 2014, 151 pts had received ≥1 dose of MEDI4736. Safety data are available for 105 pts (median age 60y; 36-84), 59% male, ECOG 0/1 (27%/71%), with a median of 3 (1-8) prior treatments, who received a median of 3 (1-8) doses. The safety profile was consistent with previous reports. Treatment-related AEs occurred in 33% of pts, with related ≥ Grade 3 AEs in 7%; none led to discontinuation of study drug. The most frequently observed treatment-related AEs were fatigue (13%), nausea (8%), rash (6%), vomiting (5%), and pyrexia (5%). One pt developed Grade 2 pneumonitis which resolved with drug interruption and steroids. There were no reports of colitis or hyperglycemia of any grade. With a median follow-up of 6 weeks, tumor shrinkage is already detectable in multiple tumor types including pts with melanoma, pancreatic, head and neck, and gastroesophageal cancer. The study continues to enroll pts and generate more mature follow-up data. Conclusions: Preliminary data in expansion suggest the safety of MEDI4736 is acceptable, even in heavily pre-treated pts. Early evidence of clinical activity was reported in multiple tumor types. Further evaluation of MEDI4736 as monotherapy and in combination with a variety of immunomodulators and targeted agents is ongoing. Clinical trial information: NCT01693562.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.32.15_suppl.3002

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 173

Metadata

Authors
Segal, N. H., Antonia, S. J., Brahmer, J. R., Maio, M., Blake-Haskins, A., Li, X., Vasselli, J., Ibrahim, R. A., Lutzky, J., & Khleif, S.
Venue
Journal of Clinical Oncology
Published
2014-05-20
Volume
32
Issue
15_suppl
Pages
3002-3002
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2474401389
Cited by
173
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.3002
The paper
Segal, N. H., Antonia, S. J., Brahmer, J. R., Maio, M., Blake-Haskins, A., Li, X., Vasselli, J., Ibrahim, R. A., Lutzky, J., & Khleif, S. (2014). Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.3002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.